ArticleBMC pediatrics2026
Clinical characterization and structural modeling of a novel de novo SPTBN1 missense variant in a Chinese child.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSPTBN1 encodes βII-spectrin, a cytoskeletal protein essential for neuronal structure and function. Pathogenic variants in this gene cause a neurodevelopmental disorder known as DDISBA (Developmental Delay, Impaired Speech, and Behavioral Abnormalities). To date, reports of SPTBN1-related disorders in the Chinese population are notably limited.
methodsTrio-based whole exome sequencing was performed to identify candidate variants, which were subsequently classified according to the ACMG classification guidelines following written informed consent. Structural modeling was subsequently conducted using AlphaFold and PyMOL to evaluate the variant’s impact on protein conformation.
resultsA Chinese male child presenting with global developmental delay, profound speech impairment, hypotonia, facial dysmorphism, and abnormal brain MRI findings was studied and reported. Trio-based whole exome sequencing identified a novel de novo, ‘likely pathogenic’, missense variant in SPTBN1 (NM_003128.3: c.471 C > G, p.Phe157Leu; Chr2:54612331, GRCh38), located in the actin-binding CH1 domain. In silico analyses suggest this variant disrupts local protein stability through significant side-chain rearrangement (Sdiff=12.75°), while maintaining overall backbone integrity (RMSD = 0.11 Å).
conclusionsThis study describes the first genetically confirmed case of DDISBA in a Chinese individual, expands the known phenotypic and genotypic spectrum of SPTBN1-related disorders and highlights the importance of variant type and population diversity in diagnosis. Structural modeling revealing significant side-chain rearrangement and increased steric hindrance suggests that local conformational disruption is a key pathogenic mechanism for the p.Phe157Leu variant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.